Related Experiment Video
Updated: Jan 10, 2026
Induction and Testing of Hypoxia in Cell Culture
Published on: August 12, 2011
Inhibition of FXa could be a novel therapeutic target associated with hypoxia-associated tumor behavior?
Ozge Bayrak1, Nazlı Mert2, Yasemin Basbinar2
1Department of Translational Oncology, Institute of Health Sciences, Dokuz Eylul University Health Campus, Balcova, Izmir, Turkey.
Background:
Factor Xa (FXa) plays a role in promoting cancer growth and metastasis via protease-activated receptors. The main aim of this study was to investigate the effect of FXa inhibition, which is known to play a crucial role in cancer metabolism in hypoxia, on the behaviour of colorectal cancer cell lines HCT116 and HT29 using FXa inhibitor-rivaroxaban.
Methods:
The studies were conducted under both normoxic and hypoxic conditions. The immunofluorescence method was used to assess the expression of key elements in tumor metabolism, including HIF1 alpha, LDHA, and GLUT1, following the administration of Rivaroxaban, which does not affect cell viability.
Results:
Hypoxia resulted in increased expression of HIF1 alpha and LDHA. However, it was observed that the expression levels decreased in the rivaroxaban-treated group. It is noteworthy that no statistically significant difference was observed in GLUT1 expression. Moreover, the analysis of E-cadherin and N-cadherin expression levels revealed that Rivaroxaban significantly impacted migration under hypoxic comparison to the control group. These findings were further corroborated by the statistical results of the wound patency in the wound healing experiment. The results reveal that the inhibition of FXa with Rivaroxaban may represent a novel target for the treatment of tumor hypoxia.
Conclusions:
The findings of this study suggest that Rivaroxaban has the potential to be both an effective anticoagulant and an anticancer agent against CRC under both hypoxic and normoxic conditions. This paper puts forward an alternative utilization method for Rivaroxaban.
Insights
Rivaroxaban, an FXa inhibitor, reduced cancer cell migration and key metabolic markers like HIF1 alpha and LDHA under hypoxia. This suggests FXa inhibition is a potential therapeutic target for colorectal cancer (CRC) treatment.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Factor Xa (FXa) promotes colorectal cancer (CRC) growth and metastasis.
- FXa plays a crucial role in cancer metabolism, particularly in hypoxic conditions.
- Investigating FXa inhibition offers a potential therapeutic strategy for CRC.
Purpose of the Study:
- To investigate the effect of FXa inhibition using rivaroxaban on colorectal cancer cell lines (HCT116 and HT29).
- To assess the impact of rivaroxaban on tumor metabolism markers under normoxic and hypoxic conditions.
- To evaluate the potential of rivaroxaban as an anticancer agent.
Main Methods:
- Colorectal cancer cell lines (HCT116, HT29) were cultured under normoxic and hypoxic conditions.
- Immunofluorescence was used to measure HIF1 alpha, LDHA, and GLUT1 expression.
- Cell migration was assessed using wound healing assays and E-cadherin/N-cadherin expression analysis.
Main Results:
- Hypoxia increased HIF1 alpha and LDHA expression, which decreased with rivaroxaban treatment.
- Rivaroxaban significantly reduced cancer cell migration under hypoxia.
- No significant change in GLUT1 expression was observed; rivaroxaban did not affect cell viability.
Conclusions:
- FXa inhibition with rivaroxaban shows potential as a novel therapeutic strategy for colorectal cancer, especially in hypoxic environments.
- Rivaroxaban may serve as both an anticoagulant and an anticancer agent for CRC.
- This study highlights an alternative application for rivaroxaban in cancer therapy.
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:23Hypoxia
Types of Hypoxia
There are four primary types of hypoxia, each resulting from a different cause:
1. Anemic hypoxia: This type occurs due to insufficient oxygen delivery caused by a lack of red blood cells (RBCs) or RBCs with abnormal or...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...